ArticleBMC rheumatology2020

Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero's adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy.

Shubhadeep Sinha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.